IDO1 and colorectal carcinoma: Combinations of IDO inhibitors with other anticancer agents, as well as the use of novel dual inhibitors, showed benefits in colorectal cancer (CRC) [26,27], pancreatic cancer [28], and hepatocellular carcinoma (HCC) [25], among others [29].